Education
About Us
Working with TipRanks
Follow Us
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
RESEARCH TOOLSreports
Top Page
Maze Therapeutics, Inc.
(NASDAQ:MAZE)
Rating:59Neutral
Price Target:―
Positive Factors
Clinical Trial Results
MZE829 has demonstrated best-in-class potential in preclinical and early clinical data, differentiating it from other APOL1 inhibitors.
Drug Development
Maze's proprietary COMPASS platform uniquely transforms human genetic variant information into mechanism-based drug programs, positioning the company as a leader in precision nephrology.
Financial Health
The company ended the quarter with $294.4M in cash and cash equivalents, which is expected to provide runway into the second half of 2027.
Negative Factors
Clinical Timeline
The company remains on track to report initial proof-of-concept data from the HORIZON study in the first quarter of 2026, which may affect investor patience.
Market Competition
MZE782 is de-risked by the positive results observed for Otsuka’s JNT-517, as both target the same mechanism, indicating competitive pressure.
Maze Therapeutics, Inc. (MAZE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$772.58M
Dividend YieldN/A
Average Volume (3M)121.44K
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees125
SectorHealthcare
Sector Strength37
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,797,165
10 Day Avg. Volume137,188
30 Day Avg. Volume121,443
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$26.75Price Target Upside51.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Maze Therapeutics, Inc. Business Overview & Revenue Model
Company DescriptionMaze Therapeutics, Inc. (MAZE) is a biotechnology company focused on translating genetic insights into novel therapeutic approaches for treating a range of diseases. Operating within the biotechnology and pharmaceutical sectors, Maze leverages its proprietary COMPASS platform to identify and validate genetic modifiers, which are then developed into potential therapeutic products. The company's core focus is on discovering genetic pathways that can be modulated to treat diseases with significant unmet medical needs.
How the Company Makes MoneyMaze Therapeutics generates revenue through a combination of strategic partnerships, collaborations, and the development and commercialization of its own therapeutic products. The company partners with other biotech and pharmaceutical companies to co-develop therapies, often receiving milestone payments and royalties from these collaborations. Additionally, Maze invests in its proprietary drug development programs, aiming to bring its therapies to market and generate revenue from product sales. The company's revenue model is heavily reliant on research and development success, regulatory approvals, and the establishment of lucrative partnerships that provide funding and market access for its innovations.
Maze Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Maze Therapeutics, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $772.58M | ― | ― | ― | ― | ||
55 Neutral | $548.62M | ― | -63.53% | ― | -47.94% | 30.94% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
49 Neutral | $1.05B | ― | 91.25% | ― | -17.75% | -19.17% | |
46 Neutral | $430.36M | ― | -75.77% | ― | ― | -44.25% | |
40 Underperform | $223.82M | ― | 87.26% | ― | ― | -43.76% |
* Healthcare Sector Average
Performance Comparison
MAZE
Maze Therapeutics, Inc.
16.45
1.45
9.67%
OMER
Omeros
3.59
-1.63
-31.23%
AKBA
Akebia Therapeutics
3.84
2.40
166.67%
SAGE
SAGE Therapeutics
8.76
-2.23
-20.29%
SVRA
Savara
2.55
-1.91
-42.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.